SCHEMBL15516453

SCHEMBL15516453

CCOC(=O)c1cc(C(C)(C)C)nn1-c1ccc(Br)cc1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ GRN P28799 1/20 0.51
▸ SORT1 Q99523 1/20 0.51
▸ ALDH1A1 P00352 3/20 0.50
▸ POLB P06746 1/20 0.50
▸ RECQL P46063 1/20 0.47
▸ CA9 Q16790 3/20 0.44
▸ LMNA P02545 1/20 0.44
▸ CA1 P00915 1/20 0.44
▸ CA2 P00918 1/20 0.44
▸ CA4 P22748 1/20 0.44
▸ SLC5A1 P13866 1/20 0.44
▸ SLC5A2 P31639 1/20 0.44
▸ CDK8 P49336 1/20 0.43
▸ HTT P42858 2/20 0.43
▸ KMT2A Q03164 2/20 0.43
▸ USP2 O75604 1/20 0.43
▸ GAA P10253 1/20 0.42
▸ MAPK1 P28482 1/20 0.42
▸ HSD17B10 Q99714 1/20 0.42
▸ CA12 O43570 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1517048 0.91 ALDH1A1 (0.59) GRNSORT1ALDH1A1POLBCA9
SCHEMBL12705321 0.87 GRN (0.68) GRNSORT1ALDH1A1POLBLMNA
SCHEMBL1107588 0.85 GRN (0.49) GRNSORT1ALDH1A1POLBCA9
SCHEMBL15485268 0.85 GRN (0.49) GRNSORT1ALDH1A1POLBCA9
SCHEMBL2924097 0.84 NTRK1 (0.52) GRNSORT1ALDH1A1POLBLMNA
SCHEMBL15517410 0.84 GRN (0.48) GRNSORT1ALDH1A1POLBCA9
SCHEMBL6420806 0.84 ALDH1A1 (0.51) ALDH1A1POLBCA9LMNACA1
SCHEMBL7373266 0.84 SMN1; SMN2 (0.51) ALDH1A1POLBCA9LMNACA1
SCHEMBL15517141 0.83 GRN (0.47) GRNSORT1ALDH1A1POLBCA9
SCHEMBL16749217 0.81 GRN (0.53) GRNSORT1ALDH1A1POLBLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9796742-B2 Kinase inhibitors RESPIVERT LIMITED (GB) 2017-10-24 — — US disclosed
EP-2890460-B1 KINASE INHIBITORS RESPIVERT LTD (GB) 2017-02-22 — — EP disclosed
US-20160340375-A1 KINASE INHIBITORS OXULAR ACQUISITIONS LIMITED (GB) 2016-11-24 — — US disclosed
US-20150210722-A1 KINASE INHIBITORS RESPIVERT LIMITED (GB) 2015-07-30 — — US disclosed
EP-2890460-A1 KINASE INHIBITORS Respivert Limited (GB) 2015-07-08 — — EP disclosed
WO-2014033446-A1 KINASE INHIBITORS RESPIVERT LIMITED (GB) 2014-03-06 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150210722-A1 KINASE INHIBITORS SYK, SRC, LYN GRN 3360/4885SORT1 3500/4885ALDH1A1 2702/4885
US-20160340375-A1 KINASE INHIBITORS SYK, LYN, BTK GRN 3218/4885SORT1 3481/4885ALDH1A1 2639/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback